Indometacin farnesil

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	None
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolism	To indometacin
Elimination half-life	1.5 hours
Excretion	Renal
Identifiers
IUPAC name (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl acetate
CAS Number	85801-02-1 Y
PubChem CID	5282183
ChemSpider	4445378 Y
UNII	MB2386WGG8
CompTox Dashboard (EPA)	DTXSID9057844
ECHA InfoCard	100.242.585
Chemical and physical data
Formula	C34H40ClNO4
Molar mass	562.15 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC=C(C)CCC=C(C)CCC=C(C)C
InChI InChI=1S/C34H40ClNO4/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-20-40-33(37)22-30-26(5)36(32-18-17-29(39-6)21-31(30)32)34(38)27-13-15-28(35)16-14-27/h9,11,13-19,21H,7-8,10,12,20,22H2,1-6H3/b24-11+,25-19+ Y Key:CFIGYZZVJNJVDQ-LMJOQDENSA-N Y
(verify)

Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.

External links

• Infree (indometacin farnesil capsules) Full Prescribing Information Archived 2010-12-03 at the Wayback Machine from Eisai Co.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

• v
• t
• e